(OHI) Omega Healthcare Investors - Overview
Stock: Skilled Nursing, Assisted Living, Care Homes, Healthcare REIT
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.95% |
| Yield on Cost 5y | 13.57% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 87.4% |
| Payout Ratio | 132.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.8% |
| Relative Tail Risk | -3.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.08 |
| Alpha | 21.25 |
| Character TTM | |
|---|---|
| Beta | 0.109 |
| Beta Downside | 0.061 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.47% |
| CAGR/Max DD | 1.69 |
Description: OHI Omega Healthcare Investors January 03, 2026
Omega Healthcare Investors (NYSE: OHI) is a publicly-traded REIT that finances and owns long-term care properties-primarily skilled-nursing and assisted-living facilities-in the United States and the United Kingdom. As of the most recent quarter (Sept 30 2025) the portfolio comprises 1,024 operating sites across 42 U.S. states, D.C., and the U.K./Jersey (including 290 U.K. care homes), managed by 88 distinct operators, plus an additional 19 facilities held through unconsolidated entities. The REIT’s stated objective is to acquire “quality” healthcare assets with strong operators to maximize a favorable risk-adjusted return for shareholders.
Key quantitative signals (as of Q3 2025) include a weighted-average lease-expiry horizon of 7.2 years, an occupancy-adjusted net operating income (NOI) margin of roughly 38 %, and a dividend yield near 6.5 %-both above the median for Health Care REITs. The sector’s fundamentals are driven by demographic aging (U.S. Medicare-eligible population projected to rise 10 % by 2030) and constrained supply of skilled-nursing beds, which historically supports rent-growth rates of 2-3 % annually. However, operator credit risk and regulatory reimbursement changes remain material uncertainties that could compress yields.
For a deeper, data-rich view of OHI’s valuation dynamics, you may find ValueRay’s interactive dashboards useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 597.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.67 > 1.0 |
| NWC/Revenue: 88.28% < 20% (prev 219.6%; Δ -131.3% < -1%) |
| CFO/TA 0.07 > 3% & CFO 649.1m > Net Income 597.3m |
| Net Debt (-27.0m) to EBITDA (941.7m): -0.03 < 3 |
| Current Ratio: 3.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (313.2m) vs 12m ago 8.97% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 12.19% > 50% (prev 10.62%; Δ 1.56% > 0%) |
| Interest Coverage Ratio: 3.78 > 6 (EBITDA TTM 941.7m / Interest Expense TTM 163.3m) |
Altman Z'' -0.05
| A: 0.11 (Total Current Assets 1.41b - Total Current Liabilities 357.4m) / Total Assets 9.63b |
| B: -0.37 (Retained Earnings -3.59b / Total Assets 9.63b) |
| C: 0.06 (EBIT TTM 616.4m / Avg Total Assets 9.77b) |
| D: 0.02 (Book Value of Equity 108.6m / Total Liabilities 4.61b) |
| Altman-Z'' Score: -0.05 = B |
What is the price of OHI shares?
Over the past week, the price has changed by +5.25%, over one month by +1.34%, over three months by +3.10% and over the past year by +29.27%.
Is OHI a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.4 | 4.6% |
| Analysts Target Price | 47.4 | 4.6% |
| ValueRay Target Price | 59 | 30.2% |
OHI Fundamental Data Overview February 07, 2026
P/E Forward = 10.1317
P/S = 12.0343
P/B = 2.4503
P/EG = 1.13
Revenue TTM = 1.19b USD
EBIT TTM = 616.4m USD
EBITDA TTM = 941.7m USD
Long Term Debt = 4.99b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 4.99b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -27.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.81b USD (13.84b + Debt 4.99b - CCE 27.0m)
Interest Coverage Ratio = 3.78 (Ebit TTM 616.4m / Interest Expense TTM 163.3m)
EV/FCF = 29.89x (Enterprise Value 18.81b / FCF TTM 629.2m)
FCF Yield = 3.35% (FCF TTM 629.2m / Enterprise Value 18.81b)
FCF Margin = 52.87% (FCF TTM 629.2m / Revenue TTM 1.19b)
Net Margin = 50.19% (Net Income TTM 597.3m / Revenue TTM 1.19b)
Gross Margin = unknown ((Revenue TTM 1.19b - Cost of Revenue TTM 10.1m) / Revenue TTM)
Tobins Q-Ratio = 1.95 (Enterprise Value 18.81b / Total Assets 9.63b)
Interest Expense / Debt = 1.16% (Interest Expense 58.1m / Debt 4.99b)
Taxrate = 21.0% (US default 21%)
NOPAT = 487.0m (EBIT 616.4m * (1 - 21.00%))
Current Ratio = 3.94 (Total Current Assets 1.41b / Total Current Liabilities 357.4m)
Debt / Equity = 0.96 (Debt 4.99b / totalStockholderEquity, last quarter 5.18b)
Debt / EBITDA = -0.03 (Net Debt -27.0m / EBITDA 941.7m)
Debt / FCF = -0.04 (Net Debt -27.0m / FCF TTM 629.2m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.12% (Net Income 597.3m / Total Assets 9.63b)
RoE = 11.98% (Net Income TTM 597.3m / Total Stockholder Equity 4.99b)
RoCE = 6.18% (EBIT 616.4m / Capital Employed (Equity 4.99b + L.T.Debt 4.99b))
RoIC = 5.00% (NOPAT 487.0m / Invested Capital 9.74b)
WACC = 4.89% (E(13.84b)/V(18.84b) * Re(6.32%) + D(4.99b)/V(18.84b) * Rd(1.16%) * (1-Tc(0.21)))
Discount Rate = 6.32% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 10.49%
[DCF Debug] Terminal Value 86.84% ; FCFF base≈662.6m ; Y1≈698.4m ; Y5≈821.5m
Fair Price DCF = 82.52 (EV 24.36b - Net Debt -27.0m = Equity 24.39b / Shares 295.5m; r=5.90% [WACC]; 5y FCF grow 5.91% → 2.90% )
EPS Correlation: 30.26 | EPS CAGR: -10.10% | SUE: 0.46 | # QB: 0
Revenue Correlation: 64.71 | Revenue CAGR: 6.81% | SUE: 3.25 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.54 | Chg30d=+0.068 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.01 | Chg30d=+0.068 | Revisions Net=+1 | Growth EPS=-1.3% | Growth Revenue=+11.2%
EPS next Year (2027-12-31): EPS=2.10 | Chg30d=+0.108 | Revisions Net=+1 | Growth EPS=+4.7% | Growth Revenue=+6.9%